News center | Australia

Dec 03, 2025

Philips Australia partners with Southern NSW Local Health District to enable Acute Care in the Home

Sydney, Australia – [December 3, 2025] –Philips, a global leader in health technology, today announced the launch of a key partnership to provide Respiree™ a wearable monitoring solution across the Southern NSW Local Health District (SNSWLHD). This landmark partnership to extend SNSWLHD’s Hospital in the Home initiative through the use of wearables, will drive better access to care, improve patient flow, reduce ED wait times, and accelerate Australia's journey toward a more proactive, digitally enabled healthcare system.

A milestone in virtual care

The announcement of the partnership to provide Respiree™  to SNSWLHD is more than just an addition of new technology; it's the result of years of close collaboration between Philips and SNSWLHD-a digitally mature health district that has consistently demonstrated leadership in reimagining care beyond the hospital walls. SNSWLHD has worked extensively with Philips on virtual health care delivery, creating a foundation of innovation and clinical readiness that will underpin this next step.

 

Helen Callum, Clinical Consultant at Philips ANZ and lead for the Respiree portfolio, described the program as “not just a technology deployment, but the continuation of a long-standing partnership with health districts who understand what it takes to bring hospital care into the community.” She added that earlier remote monitoring programs were designed primarily to spot-check patients with chronic conditions over years. This breakthrough deployment moves well beyond that, ushering in a model of continuous and scalable cardio-respiratory surveillance that can be applied across acute care, transitional care, and even into residential aged care.

 

Responding to regional realities

The partnership reflects the particular challenges of the Southern NSW health district: vast distances and scarce clinical resources have made timely access to care an ongoing challenge. In this region, virtual care is not just a convenience. It is an essential lifeline for communities spread over large rural expanses.

 

Margaret Bennett, Chief Executive, SNSWLHD said, “We look forward to this program enabling patients across our district to receive equitable, timely, and high-quality care, no matter where they live.”

 

Relieving pressure on the health system

The challenges facing Australia's hospitals continue to mount. Some emergency department wait times have tripled since 2018, while ambulance ramping and hospital over-occupancy have become daily realities across NSW [1]. For clinicians, being able to access near real-time vital sign data from patients outside the hospital offers a much-needed access to patient data.

 

The Respiree™ wearable sensors and clinical dashboards provide on-the-go alerting to enable healthcare teams to intervene earlier, prioritise resources, and reduce avoidable readmissions [2]. Some programs provide decision support algorithms that flag deterioration and help staff focus where they are most needed [3]

 

This comes at a time when the Philips Future Health Index 2025 reveals that three out of four Australian healthcare professionals (74%) are already losing valuable clinical time due to incomplete or inaccessible patient data—nearly one in five losing over 45 minutes per shift, adding up to 23 full days per year [4]. Consolidating real-time data from patients at home and in community settings, the Respiree™ solution addresses this pain point directly and saves clinicians time for what really matters: caring for the patients [5].

 

"The ability to monitor patients’ vital signs at home means our clinicians can detect a change in patient condition and provide hospital level care in the home." Ms Bennett said.

 

Better care for patients and families

For patients, the impact is deeply personal. Respiree provides a chance to recover at home, maintaining comfort and dignity while still receiving the same level of oversight that would have been available in hospital. Families are no longer forced to make long and exhausting trips to distant facilities, a change that is particularly transformative in rural areas. Through patient and caregiver apps, loved ones gain visibility into vital signs and can communicate more easily with clinical teams, helping them feel empowered and included in the care process [6]. 

 

"People will get to stay at home, in an environment they know, surrounded by family support. It will be like having the hospital right in the home with them,” Ms Bennett said.

 

GP integration is a key priority. As Callum explained, general practitioners are central to clinical governance in the care journey and the bond between primary care and hospital oversight needs to be strengthened. With mobile alerting and connected data, GPs and facility staff alike can act more quickly and make safer, more informed decisions.

Technology designed to scale

The Respiree™ solution  is an all-inclusive system that incorporates wearable IoT sensors, a clinical command centre dashboard, mobile apps for clinicians, and patient-facing applications. The sensors monitor everything from respiration rate and tidal volume to oxygen saturation, heart rate variability, and patient activity.. These streams of information run through continuous AI algorithms, trained on large and very diverse datasets, which ensure precision and reliability that clinicians can trust [7].

 

The system is designed not only to monitor but also to support broader health reform goals. FHI 2025 data shows that while 66% of Australians welcome new technology if it improves the quality of their care, more than half-53%-worry it might reduce face-to-face time with their doctor [8]. Respiree demonstrates how technology can free up time, strengthen patient-doctor relationships, and ultimately build trust by integrating AI seamlessly into workflows and making sure clinicians remain at the centre of care.


Alignment with health reform

SNSWLHD’s Hospital in the Home program supported by the Respiree™  solution, has close alignment with the NSW Health Strategy to provide Hospital in the Home services [9], one of the most ambitious health reform agendas in the country It reflects   the  Quadruple Aim by improving patient outcomes through continuous monitoring, enhancing patient experience with home-based care, empowering clinicians in both urban and rural settings, and reducing system costs through hospital substitution and avoided readmissions.

 

This program embodies the mission of Philips. "This partnership is a blueprint for how we can achieve better care for more people," said Joe Cain, Acute Care Informatics Leader, Philips APAC. "By combining innovative technology with strong clinical partnerships, we are building a future where geography and resources are no longer barriers to quality healthcare in Australia and across Asia-Pacific."

 

Philips' deployment of the Respiree™ solution throughout Southern NSW represents more than a regional success story: It is a model for what is possible nationwide. With flexibility across residential aged care, emergency department diversion, rural outreach, and transitional monitoring, Respiree offers a scalable solution that can adapt to Australia's diverse healthcare delivery needs.

 

According to Helen Callum, this is only the beginning: “The Philips Respiree platform proves that with the right technology, collaboration, and vision, we can redesign healthcare delivery in Australia.” 

References

[1] https://www.aihw.gov.au/hospitals/topics/emergency-departments/waiting-times

[2] https://www.respiree.com/index.html@p=1758.html

[3] https://www.researchgate.net/publication/396075387_Vital_Signs-Only_Machine_Learning_Model_for_Acute_Inpatient_Deterioration_A_Retrospective_Multicenter_Study

[4] https://www.philips.com.au/a-w/about/news/future-health-index/reports/2025/building-trust-in-healthcare-ai.html

[5] https://www.researchgate.net/publication/396075387_Vital_Signs-Only_Machine_Learning_Model_for_Acute_Inpatient_Deterioration_A_Retrospective_Multicenter_Study

[6] https://pubmed.ncbi.nlm.nih.gov/32449051/

[7] Respiree Pte Ltd. (2024). RS001 Cardio-respiratory Monitor: Operator’s Manual (RS001.2.D Ver 1). Retrieved from https://www.respiree.com

[8] https://www.philips.com.au/a-w/about/news/future-health-index/reports/2025/building-trust-in-healthcare-ai.html

[9] https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2025_004.pdf

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a
 leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and
enterprise informatics, as well as in personal health. Philips generated 2024
sales of EUR 18 billion and employs approximately 67,800 employees with sales
and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Click here to read moreClick here to read less

Topics

Contacts

hw headshot

Hayley Willis

Communications and Brand Manager

Philips Australia & New Zealand 

You are about to visit a Philips global content page

Continue

Media assets

Share on social media

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.

You are entering a Philips Healthcare Australia website
Please select the checkbox

The information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).

By clicking "Continue" you are indicating that you are one of the intended audience. Click cancel to be redirected to the Philips website.